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Controlled delivery of hydrophilic proteins is an important therapeutic strategy. However,
widely used methods for protein delivery suffer from low incorporation efficiency and loss
of bioactivity. The versatile interfacial polyelectrolyte complexation (IPC) fibers have the
capacity for precise spatiotemporal release and protection of protein, growth factor, and
cell bioactivity.Yet its weak mechanical properties limit its application and translation into a
viable clinical solution.To overcome this limitation, IPC fibers can be incorporated into poly-
meric scaffolds such as the biocompatible poly(vinyl alcohol) hydrogel (PVA).Therefore, we
explored the use of a composite scaffold of PVA and IPC fibers for controlled biomolecule
release. We first observed that the permeability of biomolecules through PVA films were
dependent on molecular weight. Next, IPC fibers were incorporated in between layers of
PVA to produce PVA–IPC composite scaffolds with different IPC fiber orientation.The com-
posite scaffold demonstrated excellent mechanical properties and efficient biomolecule
incorporation. The rate of biomolecule release from PVA–IPC composite grafts exhibited
dependence on molecular weight, with lysozyme showing near-linear release for 1 month.
Angiogenic factors were also incorporated into the PVA–IPC grafts, as a potential biomedical
application of the composite graft. While vascular endothelial growth factor only showed
a maximum cumulative release of 3%, the smaller PEGylated-QK peptide showed maxi-
mum release of 33%. Notably, the released angiogenic biomolecules induced endothelial
cell activity thus indicating retention of bioactivity. We also observed lack of significant
macrophage response against PVA–IPC grafts in a rabbit model. Showing permeability,
mechanical strength, precise temporal growth factor release, and bioinertness, PVA–IPC
fibers composite scaffolds are excellent scaffolds for controlled biomolecule delivery in
soft tissue engineering.
Keywords: controlled release, hydrogel, interfacial polyelectrolyte, permeability, angiogenesis
INTRODUCTION
Controlled delivery of hydrophilic, protein-based drugs is widely
explored for treatment of various diseases. It is postulated that the
sustained release of proteins to a targeted area is a more effective
method of achieving therapeutically relevant protein concentra-
tions and preventing pathological doses (Huang and Brazel, 2001).
However, currently available protein delivery systems, usually in
the form of micro- or nano-spheres, are plagued by low incorpo-
ration efficiency and loss of costly recombinant proteins, loss of
bioactivity caused by processes involving organic chemicals and
multi-step processes, and uncontrollable temporal release (King
and Patrick, 2000; Patel et al., 2008; Rui et al., 2012; Simón-Yarza
et al., 2013).
Interfacial polyelectrolyte complexation (IPC) fibers have the
characteristics that are especially pertinent for controlled release
of protein-based therapeutics such as growth factors. IPC fibers
have been utilized for precise spatiotemporal delivery of various
biomolecules such as small drugs (Liao et al., 2005), large pro-
tein growth factors (Cutiongco et al., 2014; Teo et al., 2014), or
even cells (Yim et al., 2006). Formation of IPC fibers is a self-
assembly process that occurs at the interface of two oppositely
charged polyelectrolytes in aqueous solution (Wan et al., 2004).
High incorporation efficiency of potentially any type of biomol-
ecule is possible with its addition to the similarly charged poly-
electrolyte (Cutiongco et al., 2014). Furthermore, the ambient and
aqueous conditions used for IPC fibers fabrication is advantageous
in retaining the bioactivity of incorporated biologics. The facile,
single-step fabrication of IPC fibers bestows versatility, permitting
different geometries, alignment, and combination with other tis-
sue engineering scaffolds (Cutiongco et al., 2014). Though IPC
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fibers were found to be compatible with intramuscular implan-
tation, it was found to have low tensile strength due to lack of
crystallinity and chain alignment (Yim et al., 2006). Moreover, the
small size of IPC fibers fail to provide bulk mechanical support for
most tissue engineering applications.
To overcome these structural limitations, IPC fibers can be
incorporated into polymeric materials to create composite scaf-
folds (Cutiongco et al., 2014; Teo et al., 2014). Poly(vinyl alco-
hol) (PVA) hydrogel is non-carcinogenic, non-immunogenic, and
highly biocompatible synthetic polymer that is popular for bio-
medical applications (Chaouat et al., 2008; Jiang et al., 2010). The
cross-linked hydrogel, allowing water imbibition while maintain-
ing structural integrity, has found a variety of uses in medicine
and therapy. For instance, the elastic mechanical property and
transparency of PVA make it an attractive choice for potential bio-
medical applications such as artificial cornea (Latkany et al., 1997),
heart valve stent (Wan et al., 2002), contact lens (Yang et al., 1981),
wound dressing (Taylor, 1963), and as a scaffold for drug delivery
(Nugent and Higginbotham, 2007). Like IPC fibers, the ease of
fabrication and versatile application of PVA makes it an attractive
scaffold of choice. We hypothesize that IPC fibers embedded in
PVA hydrogel will provide a composite scaffold that has tempo-
rally controllable biomolecule release, good mechanical integrity,
and biocompatibility.
In this study, we explored the use of a composite scaffold of IPC
fiber and PVA hydrogel (PVA–IPC fiber composite) as a vehicle for
the temporally controlled release of hydrophilic biomolecules. We
characterized the permeability properties of PVA hydrogel using
model molecules lysozyme and bovine serum albumin (BSA) and
observed the size- and charge-dependent permeability of PVA to
these biomolecules. To explore its potential application as a vascu-
lar graft with temporally controlled growth factor delivery, PVA–
IPC composite grafts were created. Incorporation of molecules in
PVA–IPC composite grafts ranged from 80 to 97% efficiency. PVA–
IPC composite grafts showed structural integrity and mechanical
properties matching the rabbit femoral artery. The release profiles
for AcSDKP angiogenic peptide, insulin, PEGylated-QK peptide
(PEG-QK) angiogenic factor, lysozyme, and vascular endothe-
lial growth factor (VEGF) indicated that release from PVA–IPC
grafts depended on molecular weight and hydrodynamic radius.
The release of the angiogenic factors VEGF and PEG-QK from
PVA–IPC composite grafts stimulated endothelial cell metabolism,
indicating retention of growth factor bioactivity. In vivo implan-
tation of PVA–IPC composite grafts with mechanical properties
matching rabbit femoral artery did not show significant degrada-
tion after 28 days. In addition, macrophage infiltration and capsule
formation was similar between PVA–IPC and PVA grafts, indicat-
ing similar bioinertness. Thus, we demonstrated the mechanical
integrity, capability for temporal growth factor release and bioin-
ertness of PVA–IPC fibers composite scaffolds, with a potential
application as a vascular graft.
MATERIALS AND METHODS
PREPARATION OF PVA
A 10% aqueous solution of PVA (Sigma-Aldrich, 85–124 kDa,
87–89% hydrolyzed) was prepared by dissolving PVA in distilled
deionized (DDI) water at 121°C for 20 min using an autoclave.
After mixing to ensure homogeneity, the PVA solution was used
immediately or stored at 4°C until further use. The aqueous
solution of PVA (12 g) was cross-linked by the addition of 1000µl
of 15% (w/v) sodium trimetaphosphate (STMP) (Sigma-Aldrich)
and 400µl of 30% (w/v) sodium hydroxide. To create planar
PVA films for permeability assay (see Testing PVA Permeability to
Biomolecules), glass coverslips were dipped in cross-linking PVA
solution and left to dry at 18°C for 3 days. A cylindrical mold
with a uniform outer diameter was dipped four times into a cross-
linking PVA solution, with an interval of 15 min at each dip. The
scaffolds were dried at 18°C and 60–80% humidity conditions for
3 days. Afterwards, the PVA grafts were used for making PVA–IPC
grafts (see Fabrication of PVA–IPC Grafts with Different IPC Fiber
Orientation).
TESTING PVA PERMEABILITY TO BIOMOLECULES
To assess the permeability of the PVA film to biomolecules, a leak-
proof diffusion chamber was set up. PVA planar films comprising
of four layers were mounted using a commercially available dispos-
able insert (CellCrown, Scaffdex, Finland) to get a final diffusion
area of 80 mm2. The top permeability chamber was filled with
800µl of 1.5 mg/ml aqueous solution of either lysozyme (Sigma-
Aldrich) or BSA (Sinopharm Chemical Reagent, China). The bot-
tom chamber (enclosed by the well plate) was filled with 800µl
of DDI water. The plate was incubated at 37°C and 20µl sample
volumes were drawn from both chambers at specific timepoints.
Protein concentrations were quantified using a BCA assay kit
(Pierce) and permeability coefficients were calculated as described
by Gao et al. (2008).
ENCAPSULATION OF BIOLOGICS IN PVA–IPC COMPOSITE GRAFT
Purified chitosan (Low molecular weight, >75% acetylation, 20–
300 cps; Sigma-Aldrich; 1% w/v in 0.15 M acetic acid), alginic acid
(1% w/v in DDI water), and heparin (1% w/v in DDI water) were
prepared, as described previously (Liao et al., 2005; Cutiongco
et al., 2014). Alginate and heparin (9:1 ratio) were used for incor-
poration of VEGF in IPC fibers. The addition of heparin to the
polyelectrolyte solution has been shown to attenuate the burst
release of VEGF (Cutiongco et al., 2014). Chitosan and algi-
nate or alginate-heparin solutions were drawn together to form
IPC fiber through the use of a rotating mandrel at a constant
rate of 10 mm/s. The IPC fiber was slowly drawn upward from
the interface of two polyelectrolytes and the freshly drawn end
was immediately stuck on the dry surface of a PVA film (see
Fabrication of PVA–IPC Scaffolds with Different IPC Fiber Ori-
entation), which was placed 2–2.5 cm above the polyelectrolyte
solutions (Figure 1). Five types of biologics were encapsulated in
the IPC fibers: AcSDKP peptide (Abbiotec, LLC), bovine insulin
(Sigma-Aldrich), PEGylated-QK peptide (Supplementary Mate-
rial), lysozyme, and VEGF (Life Technologies). The characteris-
tics and total mass of each biomolecule incorporated into IPC
fibers is summarized in Table 1. The total concentration of VEGF
and PEG-QK incorporated was based on the minimum require-
ments for a sustained angiogenic response in rabbit hindlimb
ischemia model (Hopkins et al., 1998). Total amount of PEG-
QK incorporated was calculated from the molar equivalent of QK
peptide necessary to simulateVEGF response (Santulli et al., 2009).
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To ensure incorporation during IPC fiber formation, negatively
charged biologics were added to alginate while positively charged
biologics were added to chitosan (Table 1). Upon IPC fiber
termination, 500µl of phosphate buffered saline (PBS) was used
to collect the residue. The concentration of biologics in this solu-
tion was used to calculate incorporation efficiency. The ratios of
chitosan:alginate used to incorporate each biomolecule is given in
Table 2.
FABRICATION OF PVA–IPC SCAFFOLDS WITH DIFFERENT IPC FIBER
ORIENTATION
Fully cross-linked PVA film with dimensions of 3.5 mm× 50 mm
with 0.5 mm thickness was mounted on the rotating mandrel and
used to collect IPC fibers. Immediately after drawing at the inter-
face using fine-tipped forceps, the end of the IPC fiber was attached
to the PVA film (Cutiongco et al., 2014). The IPC fibers were
FIGURE 1 | Incorporation of IPC fibers to create a PVA–IPC fiber
composite scaffold. Schematic diagram of PVA–IPC composite scaffold
fabrication method.
aligned either perpendicular or parallel to the long axis of the PVA
film. Thereafter, the PVA–IPC constructs were dipped to add an
additional six layers of cross-linking PVA solution (see Preparation
of PVA).
FABRICATION OF PVA–IPC GRAFTS WITH DIFFERENT IPC FIBER
ORIENTATION
To fabricate PVA–IPC grafts, PVA cylindrical scaffolds with four
layers were used (see Preparation of PVA). PVA–IPC composite
grafts with circumferential IPC alignment (Circumferential grafts)
were made by drawing IPC fibers onto a PVA cylindrical scaf-
fold mounted on rotating mandrel. IPC fibers spanned the middle
0.5 cm section of a 1 cm long graft (Figure 1). AcSDKP, lysozyme,
and VEGF were incorporated in these circumferential grafts. Bian-
gular IPC fiber alignment on composite grafts (Biangular grafts)
was achieved by oscillating the platform carrying the polyelec-
trolyte solution (8.57 mm/min) while PVA cylindrical scaffold was
mounted on a rotating mandrel. IPC fibers spanned the whole
length of the 1 cm long graft. Insulin and PEG-QK were incor-
porated in these Biangular grafts. Thereafter, IPC fibers mounted
on a PVA tubular scaffold were allowed to dry at 4°C before dip-
coating with four additional layers of cross-linking PVA. PVA–IPC
grafts were removed from the tubular mold by washing in 10X
PBS to minimize burst release of biomolecules. As a control for
bioactivity assay (see Bioactivity Assay for Released Angiogenic
Factors), standalone IPC fibers incorporated with biomolecules
were fabricated.
SEM ANALYSIS OF PVA–IPC GRAFTS
Cross-sections of grafts were air-dried overnight at ambient tem-
perature. Dried grafts were platinum coated with an approximate
thickness of 10 nm (JEOL-JFC 1600 auto-fine coater). Scanning
electron microscope (SEM) JEOL-JSM 6010LV at high vacuum
and 10 kV electrode voltage was used to visualize ultrastructure of
PVA tubes.
MECHANICAL CHARACTERIZATION OF PVA–IPC COMPOSITE
SCAFFOLDS
Wall thickness and internal diameter
Digital images of cross-sections of hydrated grafts were used to
measure wall thickness (n= 7) and internal diameter (n= 5) using
ImageJ 1.46j.
Table 1 | Properties of hydrophilic biomolecules used in this study.
Biomolecule Molecular weight (kDa) Isoelectric point Charge Hydrodynamic radius (Å) Amount (µg)
AcSDKP peptide 0.4 5.5 Negative 7a 1000
Insulin 5.73 5.3 Negative 13 111
PEG-QK 11.27 9.4 Positive 36.9a,b,c 27
Lysozyme 14.3 11.35 Positive 19.1 1200 (transwell) 350 (release)
VEGF 45.5 9.22 Positive 30.2 7.5
BSA 66.4 4.7 Negative 36.3 1200
aHydrodynamic radius of peptide with N residues predicted by formula 4.75N0.29 Å (Wilkins et al., 1999).
bHydrodynamic radius of 10 kDa PEG is 28 Å (Stiehl et al., 2013).
cHydrodynamic size of PEGylated peptide is the sum of the hydrodynamic radii of each component (Jevsevar and Kunstelj, 2012).
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Table 2 | Incorporation efficiency of various hydrophilic biomolecules
into PVA–IPC composite scaffolds.
Biomolecule Chitosan:Alginate:Heparin ratio Efficiency (%)
AcSDKP peptide 1:1:0 96.67±1.15
Insulin 1:1.7:0 91.74±2.29
PEG-QK 1:1.3:0 75.1±5.9
Lysozyme 1:1:0 78.7±8.38
VEGF 1:1.1:0.1 96.41±0.81
Uniaxial tensile test
Uniaxial testing (INSTRON 3345) was carried out on 2–3 cm
length of hydrated scaffolds (n= 3). A 10-N load cell, cross-head
speed of 10 mm/min, and gauge length of 1 cm were used. Samples
were first subjected to a pre-load of 0.1 N prior to measurement.
Planar PVA–IPC composite scaffolds were stretched until rupture
to obtain maximum tensile strength.
Radial compliance test
PVA-IPC grafts (n= 6) were subjected to internal hydrostatic pres-
sures of 80 and 120 mmHg. Images of grafts were taken at both
pressures (Nikon SMZ745T stereomicroscope) and compliance
was calculated by obtaining the percent change in the diameter of
the PVA graft between the two pressures.
Burst pressure test
Closed-ended grafts (n= 3) were progressively filled with nitrogen
gas. Burst pressure was recorded as the pressure at graft failure.
CONTROLLED RELEASE ASSAY FOR BIOMOLECULES
Each PVA–IPC composite graft was placed in a 24-well plate with
500µl of release medium. PVA–IPC grafts with AcSDKP, lysozyme,
and insulin used PBS as release medium. Release medium for Cir-
cumferential grafts with VEGF (VEGF graft) was 0.5% BSA in
endothelial basal medium (EBM, Lonza), which was then directly
used in the bioactivity assay (see Bioactivity Assay for Released
Angiogenic Factors). The amount of VEGF released at differ-
ent time points was measured using human VEGF ELISA Kit
(Life Technologies). Controlled release of Biangular grafts with
PEG-QK (PEG-QK grafts) was performed simultaneously in two
different release media. One set of samples was immersed in 500µl
of sterile PBS with 0.05% sodium azide, which was used to mea-
sure the cumulative release using PEG-ELISA, which contains the
following: Anti-PEG IgM antibodies and anti-IgM horseradish
peroxidase-conjugated antibodies (Academica Sinica) (Tsai et al.,
2001). A second set of PEG-QK grafts was immersed in 500µl
of EBM, which were subsequently used for bioactivity assay (see
Bioactivity Assay for Released Angiogenic Factors). Standalone
IPC fiber samples incorporated with VEGF or PEG-QK were
included as controls.
Cumulative release of the biomolecules was given as percentage
of the total biomolecule mass incorporated. Apparent permeabil-
ity coefficients were calculated according to Gao et al. (2008).
The slope of the initial linear portion of the controlled release
profile was used to calculate the permeability coefficient for each
biomolecule.
BIOACTIVITY ASSAY FOR RELEASED ANGIOGENIC FACTORS
Human umbilical vein endothelial cells (HUVEC, Lonza, pas-
sages 4–5) were seeded on 96-well plate at 2500 cells/well and
grown for 24 h in endothelial growth medium with 2MV bullet
kit (EGM-2MV; Lonza). Cells were then serum-deprived for 24 h
using EBM. To prevent extensive cell death, cells were afterwards
cultured in 50µl release solution supplemented with 50µl of
2X concentrated EGM-2MV, resulting in 100µl 1X EGM-2MV
media with released VEGF or PEG-QK. After 48 h of incuba-
tion with release media, 10µl of Alamar blue (Life Technologies)
was added to each well to measure cell metabolic activity. After
4 h, absorbance of Alamar blue was measured at 570 and 600 nm
(Tecan Infinite 200 PRO), as per manufacturer’s instructions. Cell
metabolic activity was reported as percent Alamar blue reduction,
which was normalized to the activity of cells grown in 0.5% BSA
in EBM (negative control). HUVEC grown in EGM-2MV supple-
mented with 10 or 50 ng/ml VEGF was used as positive control.
Each release medium sample was tested in triplicate.
IMPLANTATION OF PVA VASCULAR GRAFT IN RABBIT MODEL
Graft implantation study was performed in accordance with
approved guidelines of the Institutional Animal Care and Use
Committee of the National University of Singapore. Rabbits (New
Zealand White, Male, 3.5–4.0 kg) were sedated with ketamine
(25 mg/kg) and medetomidine (0.02 mg/kg) and maintained on
isoflurane (2–5%) plus O2 gas at 12 ml/min/kg. Enrofloxacin
(5 mg/kg) and buprenorphine (0.04 mg/kg) were administered
before surgery. After cut down and exposure of the left femoral
artery, papaverine (1.43 mg/ml) was administered topically and
intravascularly. Plain PVA (n= 3) or VEGF grafts (n= 3) with
1 cm length and 1 mm internal diameter were used. PVA grafts
were anastomosed to left femoral artery using simple interrupted
sutures (Ethilon, non-absorbable, 10-0). During this period, the
femoral artery was occluded with hemostatic arterial clamps and
heparin (100 IU/kg) was administered intravenously. In all cases,
occlusive anastomosis time did not exceed 1.5 h. Ischemic sub-
jects (positive control) were obtained through permanent lig-
ation and resection of 4 mm length of the left femoral artery.
Unoperated subjects (negative control) were also included. All
subjects were treated with enrofloxacin (5 mg/kg) and buprenor-
phine (0.04 mg/kg) for 7 days post-operatively. No anticoagulants
or antiplatelets were administered throughout the experiment.
Subjects were kept for approximately 4 weeks.
HISTOLOGICAL ANALYSIS OF PVA GRAFTS
Rabbits were euthanized with sodium pentobarbital (150 mg/kg).
Portions of the cranial abductor, semimembranous, and femoral
bicep hindlimb muscle groups surrounding the graft or the
resected femoral artery were harvested and fixed with 4%
paraformaldehyde for 48 h. Tissues were then processed and
embedded in Paraplast (Leica). Sections with 15µm thick-
ness were stained with routine hematoxylin and eosin (H&E).
Assessment of macrophage infiltration was performed through
detection of Mac-387 (Abcam) using standard immunohisto-
chemical techniques (Frangogiannis et al., 2003). Ischemic and
unoperated limbs were included as positive and negative controls,
respectively.
Frontiers in Bioengineering and Biotechnology | Biomaterials February 2015 | Volume 3 | Article 3 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cutiongco et al. Controlled release from composite hydrogel scaffold
STATISTICAL ANALYSIS
Data are presented as mean± standard deviation. Student’s t -
test was performed using GraphPad Prism v6.0 for statistical
analysis of graft mechanical properties. All other statistical analyses
were performed using ANOVA with Tukey’s post hoc test. Differ-
ences between means were considered statistically significant at
P < 0.05.
RESULTS
PERMEABILITY OF BIOMOLECULES THROUGH PVA FILM
As a preliminary test, model molecules lysozyme and BSA were
used to determine the permeability of PVA films to biomolecules
(Figure 2). Lysozyme concentrations equilibrated between the top
and bottom chambers within 24 h (Figure 2A). In contrast, the
concentrations of BSA in both top and bottom chambers remained
relatively stable over 48 h, demonstrating that BSA had minimal
diffusion through the planar PVA film (Figure 2B). The calculated
apparent permeability coefficients matched the observed relative
permeabilities of the biomolecules through PVA, where higher
permeability coefficient represents faster diffusion through PVA
(Table 3).
FABRICATION OF PVA–IPC COMPOSITE FILMS AND GRAFTS
After showing permeability of PVA to two model molecules,
we fabricated composite scaffolds that combined the controlled
release capacity of IPC fibers with PVA. Planar PVA–IPC films
were made to determine the effect of IPC fiber alignment with
respect to strain direction on mechanical properties. We observed
that elastic moduli of PVA–IPC composite films were statistically
similar regardless of IPC fiber presence or orientation (Figure 3A),
yet maximum tensile strength of each PVA–IPC film was sig-
nificantly higher than the plain PVA (Figure 3B). However, no
significant difference was observed between PVA–IPC with per-
pendicular IPC or parallel IPC. Since the parallel or perpendicular
alignment of IPC fibers along the longitudinal axis had no sig-
nificant differences in tensile strength, we fabricated PVA–IPC
composite grafts with IPC fibers arranged along the circumfer-
ential axis of the tube. These PVA–IPC grafts were fabricated as a
potential application of the composite scaffold in vascular tissue
engineering.
While PVA–IPC grafts with circumferential IPC fibers (Circum-
ferential grafts) showed a marked layer of IPC fibers in between
the inner and outer layers of PVA, composite grafts with biangular
IPC fibers (Biangular grafts) showed continuity between the PVA
layers (Figure 4). Mechanical characterization of the Circumfer-
ential and Biangular grafts showed distinct changes in properties
depending on the IPC fiber orientation. Circumferential grafts had
significantly decreased Young’s moduli, markedly reduced com-
pliance and burst pressure when compared with plain PVA grafts
(Table 4). Expectedly, we observed an increased wall thickness
in the area of the graft with IPC fibers. Nonetheless, Circum-
ferential grafts closely approximated the Young’s modulus and
compliance of rabbit femoral artery. Meanwhile, Biangular grafts
showed an opposite effect in increasing Young’s modulus and min-
imal changes in compliance when compared to plain PVA grafts
(Table 5). Burst pressure and wall thickness of Biangular grafts
were also notably reduced in comparison with plain PVA grafts.
FIGURE 2 | Permeability of hydrophilic biomolecules through PVA.
Transwell assay was used to assess permeability of (A) lysozyme and
(B) BSA through PVA film. Top chamber denotes chamber anterior to the
transwell insert, where the biomolecules were added. Bottom chamber
denotes the chamber enclosed by the tissue culture well plate and
posterior to the transwell insert, where biomolecules diffuses through.
Table 3 | Apparent permeability coefficients of biomolecules
calculated from permeability experiment.
Biomolecule Apparent permeability
coefficient (10−7 cm/s)
Lysozyme 32.98
BSA 9.723
CONTROLLED RELEASE FROM PVA–IPC COMPOSITE GRAFTS
Further examination of biomolecule permeability was performed
using PVA–IPC composite grafts that were incorporated with
molecules smaller than BSA. The incorporation efficiency of vari-
ous biomolecules in PVA–IPC composite grafts were optimized by
varying the ratio between alginate, chitosan, and heparin (Table 2).
AcSDKP release showed burst release until 12 h, with dimin-
ishing release rates that began at 24 h after immersion in release
medium (Figure 5A). Insulin showed a similar release profile,
with a very rapid release within the first 4 h (Figure 5B). Max-
imum release of 58% insulin was achieved after 24 h. In contrast
to AcSDKP, cumulative lysozyme release was nearly linear and with
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FIGURE 3 | Mechanical properties of PVA–IPC composite films with
IPC fibers in different orientations. (A) Elastic modulus and
(B) maximum tensile strength of PVA–IPC composite films compared
with plain PVA film. Orientation of IPC fibers are given with respect to
the longitudinal axis of the PVA film and direction of strain. *Denotes
statistical significance.
FIGURE 4 | PVA–IPC composite grafts. (A) Schematic diagram of
composite grafts with circumferential alignment and biangular
alignment of IPC fibers. Dashed line shows cross-section area imaged
with SEM. (B) SEM image showing the cross-section of different types
of PVA–IPC composite grafts compared with plain PVA graft.
Scale bar=200µm.
Table 4 | Mechanical properties of PVA–IPC composite grafts with circumferential IPC fibers.
Scaffold type Internal diameter
(µm)
Wall thickness
(µm)
Young’s modulus
(kPa)
Compliance
(%)
Burst pressure
(mmHg)
Plain PVA 1150±72.93 312.7±42.54 562.9±144.2* 8.171±3.463 492.2±66.88
Circumferential composite graft 1072±73.85 598.4±120.9
(part with IPC
fiber)
125.7±37.78* 4.810±5.050 269.4±134.1
Rabbit femoral artery 938±201 350 230 5.9±0.5 2031–4225
*Denotes statistical significance between composite scaffold and plain PVA graft.
minimal burst release at early timepoints (Figure 5C). However,
there was a noted decrease in release rate from 284 h (16 days)
timepoint, where the release profile started to show a diminishing
rate of release. Maximum lysozyme release of 77% was reached
in 92 days. Apparent permeability coefficients calculated from
PVA–IPC grafts matched the release profiles observed (Table 6).
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Table 5 | Mechanical properties of PVA–IPC composite graft with biangular IPC fibers.
Scaffold type Internal diameter (µm) Wall thickness (µm) Young’s modulus (kPa) Compliance (%) Burst pressure (mmHg)
Plain PVA 2690±101.2 375.8±79.6* 352.3±32.59* 4.88±0.24 310.9
Biangular composite graft 1963±76.86 311.3±29.0* 830.5±116.8* 5.23±2.8 202.6±101.9
*Denotes statistical significance between composite scaffold and plain PVA graft.
FIGURE 5 | Controlled release of biomolecules through PVA–IPC
composite grafts. Cumulative release profile of (A) AcSDKP, (B) insulin,
and (C) lysozyme from PVA–IPC composite grafts.
Modifying the number of outer layers of PVA did not show any
change in release profile or maximum cumulative release achieved
for lysozyme and BSA (Figure S2 in Supplementary Material).
Table 6 | Apparent permeability coefficient of hydrophilic biomolecules
calculated from controlled release experiments using PVA–IPC
composite grafts.
Biomolecule Apparent permeability
coefficient (10−7 cm/s)
AcSDKP peptide 2.18
Insulin 0.529
PEG-QK 0.43
Lysozyme 0.218
VEGF 0.162
CONTROLLED RELEASE OF BIOACTIVE ANGIOGENIC MOLECULES VEGF
AND PEG-QK
Thereafter, we demonstrated the use of the PVA–IPC composite
grafts with circumferential IPC fibers for the controlled release of
angiogenic growth factor VEGF (VEGF graft). Since the molecu-
lar weight of VEGF was less than BSA, we postulated that VEGF
would be permeable through the composite grafts. Overall, VEGF
release profile was similar for both standalone IPC fibers loaded
with VEGF (VEGF–IPC fibers) and VEGF grafts. Standalone IPC
fibers achieved a maximum cumulative release of 23.40± 0.51%
yet only a maximum release of 2.03± 0.07% VEGF was observed
from VEGF grafts after 19 days (Figure 6A). Furthermore, release
from VEGF graft achieved a release plateau starting from 171 h
(7.1 days).
The bioactivity of released VEGF was also assessed by mon-
itoring HUVEC metabolic activity using Alamar blue assay
(Figure 6B). Alamar blue reduction levels were statistically sim-
ilar for VEGF released from graft or standalone IPC fibers.
HUVEC metabolic activity using release media from both scaf-
folds markedly decreased at 171 h, which marked the plateau
of VEGF release. It was notable that the Alamar blue reduction
levels were statistically similar to what was induced by supple-
mented 50 ng/ml VEGF. This indicates that there is good preser-
vation of VEGF bioactivity in both IPC and PVA–IPC composite
scaffolds.
VEGF release profile implied its limited diffusion through PVA
despite having a molecular weight lower than BSA. We then aimed
to use an angiogenic molecule that can mimic the charge and
molecular weight of lysozyme (Table 1). QK peptide, an angio-
genic molecule that mimics the bioactive helix of VEGF (Finetti
et al., 2012) was PEGylated to increase its molecular weight to the
range of the lysozyme molecular weight (Supplementary Mater-
ial). PEG conjugation of QK did not change its bioactivity (Figure
S1 in Supplementary Material) and was incorporated in PVA–IPC
composite grafts (PEG-QK graft) to study its release behavior.
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FIGURE 6 | Controlled release of VEGF from PVA–IPC composite graft with circumferential IPC fibers. (A) Cumulative release profile of VEGF from VEGF
composite grafts compared with standalone VEGF-IPC fibers. (B) Bioactivity of released VEGF measured by Alamar blue percent reduction.
FIGURE 7 | Controlled release of PEG-QK from PVA–IPC composite graft with biangular IPC fibers. (A) Cumulative release profile of PEG-QK from
PEG-QK composite graft compared with standalone PEG-QK-IPC fibers. (B) Bioactivity of released PEG-QK measured by Alamar blue percent reduction.
In general, the release profile of PEG-QK from both PEG-
QK-IPC fibers and PEG-QK grafts were similar (Figure 7A). For
both types of scaffolds, an initial rapid release was followed by
a diminished rate of release. Similar to VEGF release profile, a
higher maximum PEG-QK release was achieved from standalone
IPC fibers at 46% in comparison to PEG-QK grafts, achieving
maximum of 33% in 5 days.
Release medium from both PEG-QK-IPC fibers and PEG-QK
graft had a positive effect on HUVEC metabolic activity, signi-
fying the bioactivity of PEG-QK (Figure 7B). Compared with
supplemented VEGF, the bioactivity of released PEG-QK was
found to be markedly lower than 10 ng/ml VEGF. Nonetheless,
the observed bioactivity of PEG-QK was consistent through all
timepoints and showed no significant differences between media
from either PEG-QK-IPC fibers or PEG-QK grafts.
PROOF-OF-CONCEPT: FEASIBILITY OF PVA–IPC COMPOSITE GRAFT
IMPLANTATION IN RABBIT MODEL
Afterwards, VEGF grafts were anastomosed to the rabbit femoral
artery. VEGF grafts were chosen because of the higher bioactiv-
ity of VEGF retained in comparison to PEG-QK. Both the VEGF
and PVA grafts were easily anastomosed to the rabbit femoral
artery (Figure 8A), resulting in maximum ischemia time of only
1 h and 30 min. Surgical sites appeared normal and without edema
throughout recovery. All animal subjects showed alertness, respon-
siveness, normal appearance, and mobility at 28 days. No systemic
abnormalities were observed for any of the rabbit subjects.
Histological analysis of the PVA grafts after 28 days of
implantation showed that both VEGF grafts and plain PVA grafts
did not show any signs of degradation (Figure 8B). However,
stenosis of the VEGF graft was observed (Figure 8B). A thin layer
of connective tissue or capsule was seen around the VEGF grafts,
in contrast to PVA grafts (Figure S3 in Supplementary Mater-
ial). Standard H&E stains of hindlimb muscles show rounded
and bundled muscle fibers around PVA and VEGF grafts. These
hindlimb muscles closely resembled the normal physiological
hindlimb muscles in the unoperated control. Macrophage infil-
tration was also assessed through histology to determine acute
inflammation against plain PVA and VEGF grafts. Mac-387 stain-
ing was similar in hindlimb muscles surrounding PVA graft and
VEGF graft (Figure 8C). In addition, hindlimb muscles from both
PVA and VEGF grafts showed Mac-387 stain density similar to
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FIGURE 8 | Proof-of-concept implantation of PVA–IPC composite graft
in rabbit femoral artery. (A) Representative PVA graft and VEGF graft
implanted in rabbit femoral artery. Black arrows represent anastomosis of
graft to femoral artery. White arrow denotes location of circumferential IPC
fibers. (B) Hematoxylin and eosin (H&E) stain against plain PVA graft and
VEGF graft. (i) Shows overview of grafts (10X). Box indicates magnified
area shown in (ii) (20X). Blue arrows denote PVA layers, dashed line
denotes the IPC fiber layer in the VEGF grafts and *denotes the lumen of
the grafts. (C) H&E stain and IHC stain against Mac-387 on various
hindlimb tissues surrounding the graft (20X). Unoperated hindlimb and
ischemic hindlimb were used as negative and positive controls,
respectively. Brown color denotes positive stain for Mac-387.
an unoperated hindlimb. Meanwhile, ischemic muscles showed
angular muscle fibers with large bundle separation and a higher
density of Mac-387 positive stain compared with the unoperated
control. Connective tissues surrounding PVA and VEGF grafts
also showed similarities in staining against Mac-387 (Figure S3 in
Supplementary Material).
DISCUSSION
Therapeutic protein delivery, local concentration, and bioactivity
must be strictly controlled to induce stable and therapeutic effects
in vivo (Lee et al., 2011). For example, the lack of clinical benefit
of VEGF in clinical trials is caused by indiscriminate growth fac-
tor delivery (Rajagopalan et al., 2003). Despite this critical need,
many bioengineered platforms for hydrophilic protein delivery
are inefficient and incapable of retaining bioactivity. Moreover,
this leads to a large amount of protein loss that can be expensive
and wasteful. IPC fibers are easily fabricated in ambient and aque-
ous conditions, leading to efficient biomolecule incorporation and
high biomolecule activity. However, IPC fibers are limited in ther-
apeutic application due to its weak mechanical properties. PVA
cross-linked with food-grade STMP (Andersen, 2001) supplies a
good scaffold for controlled biomolecule delivery due to its desir-
able mechanical (Chaouat et al., 2008) and biocompatible (Ino
et al., 2013) characteristics through a simplistic preparation in
aqueous and ambient conditions.
As a possible solution, we combined PVA and IPC fibers to
create bioinert, mechanically-strong composite scaffolds for con-
trolled delivery of biomolecules. We observed that PVA showed
size-dependent permeability toward biomolecules from the tran-
swell experiments. The large molecule BSA diffused poorly
through PVA films while the relatively smaller molecule lysozyme
equilibrated across the PVA membrane. Similarly, we observed the
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same relationship for biomolecule movement through PVA–IPC
composite grafts, which was used to demonstrate the potential
application of the composite scaffold. Low molecular weight AcS-
DKP (Wilkins et al., 1999) and insulin showed fast release within
24 h, whereas lysozyme showed a more sustained long term release.
Our results are analogous with those of Matsuyama et al. (1997),
who observed decreased diffusion of large molecules because of
the small mesh size of the glutaraldehyde-cross-linked PVA hydro-
gel. In contrast, our PVA is cross-linked by STMP, thus creating a
hydrogel with physical and chemical characteristics that differen-
tiates it from glutaraldehyde-cross-linked PVA. For instance, our
PVA putatively contains negatively charged phosphate linkages
(Leone et al., 2010; Ino et al., 2013) that may cause electro-
static repulsion against negatively charged biomolecules such as
BSA and insulin. This agrees with Shalviri et al.’s (2010) work
on the permeability of negatively charged polysaccharide mem-
branes to different molecules. The group showed that molecules
of opposite charge to the polysaccharide membrane had a nearly
fivefold increase in permeability compared to molecules of similar
molecular weight but possessing the same charge polarity as the
membrane. Hydrophilicity may also be a determining factor in
the movement of molecules through the highly hydrophilic PVA
hydrogel network.
Though VEGF had a molecular weight lower than BSA, we
still observed non-optimal diffusion of this growth factor through
PVA–IPC grafts. We then sought to use an angiogenic peptide
that had a molecular weight similar to lysozyme. PEG-QK peptide
showed a similar release profile to VEGF, albeit at a higher cumu-
lative release percentage. While the rate of release remained largely
the same for either VEGF or PEG-QK, the cumulative release from
standalone IPC fibers always exceeded that of the composite scaf-
fold. Based on our permeability experiments and the similarity of
release profiles from both IPC fibers and composite scaffold, we
postulate that the PVA may be the limiting step in rate of biomol-
ecule release from the composite scaffolds. Moreover, our results
strongly suggest the release from both IPC and PVA–IPC scaffolds
can be determined by Fickian diffusion, which is characterized by a
diminishing release rate over time (Ritger and Peppas, 1987). The
impermeable PVA barrier in PVA–IPC scaffolds further controls
release rate, as governed by biomolecule weight and hydrodynamic
size (Matsuyama et al., 1997). This is further supported by the con-
trast in release profile between lysozyme and PEG-QK, (Jevsevar
and Kunstelj, 2012; Stiehl et al., 2013) which have similar mole-
cular weights but marked difference in hydrodynamic radius. In
contrast, our previous study demonstrated near-linear release of
BSA from a composite scaffold made from IPC fibers embedded
in porous STMP-cross-linked polysaccharide hydrogel (Cutiongco
et al., 2014). Thus, it may be advantageous to change PVA per-
meability through addition of non-hazardous porogens such as
sodium chloride salts. Changing the crystallinity of PVA by using
different acetylated and hydrated species of PVA molecules can
also change biomolecule movement (Nugent and Higginbotham,
2007).
Aside from the significance of precise temporal release in
growth factor therapy, it is necessary to deliver bioactive growth
factors to produce a therapeutic effect. We noted the bioactiv-
ity of both VEGF and PEG-QK despite the alkaline environment
to crosslink the PVA. Notably, there were no significant differ-
ences in Alamar blue reduction between IPC fibers and PVA–IPC
grafts at any timepoint. In comparison with supplemented VEGF,
our results indicate that there is retention of bioactivity when
using PVA–IPC scaffolds. Overall, the aqueous and ambient condi-
tions used for PVA–IPC scaffold fabrication retained the ideal IPC
fiber property of protecting growth factor activity. Coupled with
high biomolecule incorporation efficiency, PVA–IPC scaffolds are
advantageous for therapeutic angiogenesis with significantly lower
loss of expensive growth factor and reduced manufacturing cost.
While the most important function of IPC fibers is the temporal
control of biologics delivery, it must also be noted that the flex-
ibility of manipulating IPC fibers allows control of its geometry,
orientation, and incorporation into any type of scaffold. Specif-
ically, IPC fibers were molded while being drawn from the poly-
electrolyte solution. With this method, we were able to incorporate
IPC fibers onto PVA scaffolds with two different orientations. In
both circumferential and bidirectional angular orientations, IPC
fibers were integrated in between PVA layers without hindering
crosslinks between the PVA layers. The versatility of dictating
both IPC fiber geometry coupled with PVA macromolding per-
mits the use of the composite scaffold for other tissue engineering
applications such as wound dressing or peripheral nerve graft.
In addition, the superb mechanical strength of PVA–IPC com-
posite scaffolds is desirable for in vivo applications, such as a
bioactive vascular graft with growth factor or drug delivery. It was
previously demonstrated that PVA mechanical properties can be
easily tuned to approach native arterial characteristics (Chaouat
et al., 2008). While plain PVA grafts exhibited mechanical strength,
the addition IPC fibers were able to further tweak the mechanical
properties to more closely approximate the rabbit femoral artery.
We observed that the orientation of IPC fiber alignment produced
different effects on mechanical characteristics. Concentration of
IPC fibers in the circumferential arrangement may create an area
of discontinuity that decreases elastic modulus, compliance, and
burst pressure. Biangular grafts, on the other hand, had more
widely and uniformly distributed IPC fibers that may be more
beneficial in spreading mechanical load thus leading to increased
elastic modulus while retaining radial compliance. Nonetheless,
the mechanical characteristics of circumferential grafts that closely
approximated the rabbit femoral artery facilitated anastomo-
sis and reduced vessel injury, and decreasing surgery time and
post-operative complications.
In vivo implantation of PVA or VEGF grafts for 28 days did
not result in drastic or macroscopic change in graft structure. The
lack of clinical (e.g., edema) or histological manifestations of local
inflammation and the similarities in capsule formation demon-
strated that PVA–IPC composite grafts have similar bioinertness
as PVA grafts. Nonetheless, the luminal stenoses of the grafts due
to possible thrombosis or neointimal growth imply that further
fine-tuning of the mechanical and biomolecule release properties
of the VEGF grafts could be performed.
Dual release of growth factors is important for synergisti-
cally inducing angiogenesis (Hao et al., 2007). Recently, Han
et al. (2013) showed the dual delivery of VEGF and platelet
derived growth factor from electrospun vascular grafts. Despite
the impressive release profile of growth factors, they only
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demonstrated maximum 20% incorporation efficiency and lack
of radial compliance. Use of IPC fibers provide a more versatile
method for efficient multiple growth factor incorporation that is
not limited to heparin-binding factors. IPC fiber technique is not
limited to growth factors and may also be used for cell, DNA,
or microparticle delivery for therapeutic angiogenesis (Yim et al.,
2006; Tai et al., 2010; Yow et al., 2011). Most notably, our PVA–IPC
scaffold can be fabricated in aqueous and ambient conditions that
aid the preservation of growth factor bioactivity thus, increasing
its application in therapy.
In summary, we have shown the potential of PVA–IPC
composite scaffolds as a new platform for controlled hydrophilic
biomolecule delivery. Firstly, we showed the size-dependent
permeability of hydrophilic molecules through PVA. Secondly,
we showed that PVA–IPC composite scaffolds showed excellent
mechanical properties that were modulated by IPC fiber align-
ment. Thirdly, PVA–IPC composite tubular scaffold was fabricated
to demonstrate its application as a vascular graft. Fourthly, con-
trolled release of hydrophilic molecules through PVA–IPC com-
posite scaffolds were also demonstrated through a systematic study
of various model molecules, where lysozyme showed near-linear
release for 30 days. Significantly, PVA–IPC grafts showed reten-
tion of angiogenic growth factor bioactivity. Finally, PVA–IPC
grafts were implantable in a rabbit model and showed bioinert-
ness, eliciting a similar local inflammatory response as PVA grafts.
PVA–IPC fiber composite scaffolds represent an excellent plat-
form growth factor delivery for various applications in soft tissue
engineering.
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